Entera Bio (NASDAQ:ENTX) Announces Earnings Results

Entera Bio (NASDAQ:ENTX) issued its quarterly earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05), FiscalAI reports.

Entera Bio Stock Up 5.0%

Shares of Entera Bio stock traded up $0.15 during trading on Friday, hitting $3.14. The stock had a trading volume of 117,978 shares, compared to its average volume of 598,459. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20. The stock has a 50 day simple moving average of $2.88 and a 200 day simple moving average of $1.95. The company has a market capitalization of $546.11 million, a PE ratio of -8.97 and a beta of 1.48.

Analyst Upgrades and Downgrades

ENTX has been the subject of several recent research reports. Leerink Partners started coverage on shares of Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 target price for the company. Guggenheim began coverage on shares of Entera Bio in a research report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target on the stock. Lifesci Capital initiated coverage on Entera Bio in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald started coverage on Entera Bio in a research note on Tuesday, September 22nd. They set an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.60.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.